Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can we predict which kids will respond to migraine meds?

NCT ID NCT07180043

First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 34 times

Summary

This completed study in 178 children aged 6-16 with migraine compared propranolol (a blood pressure medicine) to behavioral therapy (education and lifestyle changes) over 12 weeks. The main goal was to see which children responded best to propranolol by looking at factors like anxiety, vertigo, and vitamin levels. The aim is to help personalize migraine prevention in kids.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEDIATRIC MIGRAINE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Kayseri University

    Kayseri, Kayseri, 38130, Turkey (Türkiye)

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Propranolol

What this could lead to

If successful, this could help doctors predict which children with migraine will benefit from propranolol, leading to more personalized and effective treatment.

What could go wrong

This is an observational analysis of a completed trial, not a new treatment test. The findings may not apply to all children and need further validation.

Conditions

The condition(s) this trial relates to.

headache disorder migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.